Multiple sclerosis (MS) patients undergoing anti-CD20 (aCD20) treatment which depletes the B cells that contribute to the MS attacks are able to mount robust T-cell responses to the mRNA COVID-19 vaccines, despite having a muted antibody response to the vaccines, researchers suggest.
Multiple Sclerosis Patients Show Robust T-Cell Responses to mRNA COVID-19 Vaccines ptproductsonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ptproductsonline.com Daily Mail and Mail on Sunday newspapers.
Oncocyte Hosting Two-Part Key Opinion Leader Event Series streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
New research shows that Multiple Sclerosis (MS) patients undergoing anti-CD20 (aCD20) treatment – which depletes the B cells that contribute to the MS attacks – are able to mount robust T-cell responses to the mRNA COVID-19 vaccines, despite having a muted antibody response to the vaccines.
MS patients receiving aCD20 treatment mount robust T-cell responses to COVID-19 vaccines news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.